Creative Medical Technology Holdings, Inc. (CELZ) is a Biotechnology company in the Healthcare sector, currently trading at $2.29. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Valuation: CELZ trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.24.
Financials: revenue is $6,000, -37.7%/yr average growth. Net income is $6M (loss), growing at +11.4%/yr. Net profit margin is -99916.8% (negative). Gross margin is -1992% (-2059.8 pp trend).
Balance sheet: total debt is $0 against $8M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 25.97 (strong liquidity). Debt-to-assets is 0%. Total assets: $8M.
Analyst outlook: 1 / 1 analysts rate CELZ as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
